GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26/10/26	NT$21.50	+0.23%	86,428
22/10/26	NT$21.45	-1.38%	73,146
21/10/26	NT$21.75	+0.23%	26,151
20/10/26	NT$21.70	+0.46%	70,260

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 27/10/2026			5-day change	1st Jan Change
21.50 ^TWD	+0.23%		-0.46%	-16.50%

08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-03	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI

Market Cap	2.42B 74.6M 66.96M 61.83M 56.06M 105M 7.09B 106M 741M 294M 3.71B 280M 274M 11.78B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.2B 67.83M 60.88M 56.21M 50.97M 95.27M 6.44B 96.44M 674M 268M 3.38B 255M 249M 10.71B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-03	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
06-11	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
05-14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
03-23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
03-13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
11-24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
11-14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/10/25	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
29/10/25	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
13/08/25	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

1 day	+0.23%
1 week	-0.46%
Current month	-3.80%
1 month	-2.05%
3 months	-6.72%
6 months	-4.87%
Current year	-16.50%

GlycoNex Incorporation Share Price

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news: GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Price Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	21.05	22.05
1 month	21.05	23.55
Current year	21.05	30
1 year	20.55	30
3 years	15.6	31.85
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	31/12/2018
Dih Fen Wu DFI	Director of Finance/CFO	-	31/12/2009
Yao Hua Lue IRC	Investor Relations Contact	-	11/11/2012

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	31/01/2001
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	24/05/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	+0.23%	-0.46%	-9.66%	-21.25%	74.05M
WUXI APPTEC CO., LTD.	-3.10%	-3.43%	+36.29%	+67.69%	65.28B
ARGENX SE	+0.33%	+0.33%	+10.16%	+78.07%	54.57B
LONZA GROUP AG	+0.16%	+1.73%	+9.89%	+102.10%	53.59B
IQVIA HOLDINGS INC.	-0.59%	+1.69%	+25.27%	+51.38%	45.03B
BEONE MEDICINES AG	-1.95%	-5.49%	+15.21%	+113.21%	42.17B
REVOLUTION MEDICINES, INC.	+1.00%	-5.52%	+220.24%	+897.90%	39.42B
CELLTRION, INC.	-0.74%	-4.84%	+14.53%	+44.45%	32.71B
WUXI BIOLOGICS (CAYMAN) INC.	-2.70%	-7.34%	+23.17%	+0.36%	24.01B
GENMAB A/S	+1.11%	+15.18%	+60.27%	+49.33%	26.5B
Average	-0.63%	+1.73%	+40.54%	+138.32%	38.33B
Weighted average by Cap.	-0.80%	+1.72%	+43.15%	+154.95%

	2024	2025
Net sales	14.7M 453K 407K 376K 341K 637K 43.06M 645K 4.5M 1.79M 22.57M 1.7M 1.67M 71.58M	37.86M 1.17M 1.05M 968K 877K 1.64M 111M 1.66M 11.6M 4.61M 58.13M 4.38M 4.29M 184M
Net income	-230M -7.08M -6.36M -5.87M -5.32M -9.95M -673M -10.07M -70.38M -27.95M -353M -26.59M -26.02M -1.12B	-235M -7.25M -6.51M -6.01M -5.45M -10.19M -689M -10.31M -72.07M -28.62M -361M -27.23M -26.65M -1.15B
Net Debt	-442M -13.63M -12.24M -11.3M -10.25M -19.15M -1.3B -19.38M -135M -53.8M -679M -51.18M -50.08M -2.15B	-220M -6.78M -6.08M -5.61M -5.09M -9.52M -644M -9.63M -67.32M -26.73M -337M -25.43M -24.89M -1.07B